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Fine mapping and identification 
of serum urate loci in American 
Indians: The Strong Heart Family 
Study
Geetha chittoor1,2, Karin Haack3, Poojitha Balakrishnan4, Christopher Bizon5, 
Sandra Laston6, Lyle G. Best7, Jean W. Maccluer3, Kari E. north8, Jason G. Umans9, 
Nora franceschini8, Gauri prasad10,11, Luis Macias-Kauffer  12, Teresa Villarreal-Molina12, 
Dwaipayan Bharadwaj11,14, Samuel canizales-Quinteros13, Ana navas-Acien4, Shelley A. cole3 
& V. S. Voruganti1*
While studies have reported genetic loci affecting serum urate (SU) concentrations, few studies 
have been conducted in minority populations. Our objective for this study was to identify genetic 
loci regulating SU in a multigenerational family-based cohort of American Indians, the Strong Heart 
Family Study (SHFS). We genotyped 162,718 single nucleotide polymorphisms (SNPs) in 2000 
SHFS participants using an Illumina MetaboChip array. A genome-wide association analysis of SU 
was conducted using measured genotype analysis approach accounting for kinships in SOLAR, and 
meta-analysis in METAL. Our results showed strong association of SU with rs4481233, rs9998811, 
rs7696092 and rs13145758 (minor allele frequency (MAF) = 25–44%; P < 3 × 10−14) of solute carrier 
family 2, member 9 (SLC2A9) and rs41481455, rs2231142 and rs1481012 (MAF = 29%; p < 3 × 10−9) 
of ATP-binding cassette protein, subfamily G, member 2 (ABCG2). Carriers of G alleles of rs9998811, 
rs4148155 and rs1481012 and A alleles of rs4481233, rs7696092 and rs13145758 and rs2231142 had 
lower SU concentrations as compared to non-carriers. Genetic analysis of SU conditional on significant 
SLC2A9 and ABCG2 SNPs revealed new loci, nucleobindin 1 (NUCB1) and neuronal PAS domain protein 
4 (NPAS4) (p <6× 10−6). To identify American Indian-specific SNPs, we conducted targeted sequencing 
of key regions of SLC2A9. A total of 233 SNPs were identified of which 89 were strongly associated with 
SU (p < 7.1 × 10−10) and 117 were American Indian specific. Analysis of key SNPs in cohorts of Mexican-
mestizos, European, Indian and East Asian ancestries showed replication of common SNPs, including 
our lead SNPs. Our results demonstrate the association of SU with uric acid transporters in a minority 
population of American Indians and potential novel associations of SU with neuronal-related genes 
which warrant further investigation.
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Hyperuricemia or elevated concentration of urate in serum (SU) is a risk factor for gout, hypertension, chronic 
kidney disease (CKD) and cardiovascular disease (CVD)1–4. Uric acid is the final product of purine metabolism in 
humans, and urate homeostasis involves balancing its production with secretion and reabsorption in the proximal 
convoluted tubule of kidneys3,4. The variation in SU concentration is under significant genetic influence and its 
pattern of inheritance suggests that many genes may influence it1. Correspondingly, the renal transport of urate 
involves several genes including solute carrier family 2, member 9 (SLC2A9), ATP-binding cassette ABC, sub-
family G, member 2 (ABCG2), solute carrier family 22, members 11 and 12 (SLC22A11 and SLC22A12), solute 
carrier family 17, members 1, 3 and 4 (SLC17A1, SLC17A3 and SLC17A4), and solute carrier family 16, member 
9 (SLC16A9). Most of these genes have been associated with hyperuricemia1–6.
Both hyper and hypouricemia have been linked to increased risk for metabolic diseases. While hypouricemia 
has been linked to neurological disorders such as multiple sclerosis and Parkinson’s disease7,8, hyperuricemia is 
causal for gout and nephrolithiasis and seems to increase the risk for CKD and CVD1–4. Originally thought to 
be just a marker, SU’s role in development and progression of these diseases is being increasingly recognized3. 
While a recent review by Li et al.9 found no clear role for uric acid in metabolic diseases other than gout and 
nephrolithiasis, many studies including ours, have shown that gout patients and asymptomatic hyperuricemic 
individuals tend to be at high risk for CVD and CKD (Table 1)10,11. Therefore, it is essential to understand the 
genetic and environmental factors that affect the variation in SU. Even though genome-wide association studies 
(GWAS) have identified many SU-related loci, the majority of these studies have been conducted in European, 
African American and Asian populations12–22. To better understand genetic variation, biological significance and 
translation to human health, it is important to study ethnically diverse populations23. Further, the linkage disequi-
librium (LD) pattern differences in ethnically diverse populations may offer a unique perspective on fine mapping 
of genetic loci.
American Indians are such a population that is understudied and underrepresented in genetic databases. The 
prevalence of CVD and CKD is high in American Indians with heart disease being the leading cause of death 
[https://www.cdc.gov/dhdsp/data_statistics/fact_sheets/fs_aian.htm]. The Strong Heart Family Study (SHFS) 
is a multigenerational family-based study of CVD in American Indians. This cohort has high rates of obesity, 
diabetes, CKD and CVD24–26. In addition, about 25% of individuals have hyperuricemia (SU > 6 mg/dl)27. Thus, 
our aim in this study was to identify the genetic loci that regulate SU concentrations in American Indians. The 
Phenotype* Normouricemia Hyperuricemia** P value
Anthropometric
Body weight (kg) 88.08 (24.1) 97.79 (23.8) <0.0001
Waist circumference (cm) 103.57 (18.8) 107.59 (18.0) <0.0001
BMI (kg/m2) 33.04 (8.2) 34.38 (7.3) NS
Lipids
Total cholesterol (mg/dl) 177.46 (34.6) 189.74 (42.3) <0.0001
HDL cholesterol (mg/dl) 51.56 (14.6) 48.26 (14.1) <0.0001
LDL cholesterol (mg/dl) 95.92 (28.1) 104.39 (31.8) <0.0001
Triglycerides (mg/dl) 156.65 (129) 200.44 (254) <0.0001
ECHO measures
Heart rate (BPM) 66.99 (10.6) 67.38 (11.5) NS
Left ventricular mass (g) 152.72 (39.0) 175.27 (41.7) <0.0001
Relative wall thickness 0.298 (0.04) 0.301 (0.04) 0.030
Stroke volume (ml) 80.81 (14.5) 84.90 (15.1) <0.0001
Ejection fraction  60.41 (5.7) 58.63 (5.8) <0.0001
Cardiac output (ml/min) 5376.44 (1153) 5673,0.78 (1252) <0.0001
Total peripheral resistance (dyne/cm/sec) 1410.02 (304) 1392.27 (316) NS
Blood pressure
Systolic (mmHg) 121.25 (17.2) 126.56 (15.8) <0.0001
Diastolic (mmHg) 75.47 (11.0) 78.46 (11.6) <0.0001
Carotid measures
Left common carotid diastolic diameter (mm) 5.67 (0.7) 6.00 (0.7) <0.0001
Right common carotid diastolic 
diameter (mm) 5.78 (0.7) 6.10 (0.7) <0.0001
Left common carotid systolic diameter (mm) 6.40 (0.7) 6.78 (0.7) <0.0001
Right common carotid systolic diameter (mm) 6.51 (0.7) 6.87 (0.8) <0.0001
Left common carotid artery intimal medial 
thickness (mm) 0.66 (0.2) 0.69 (0.2) <0.0001
Right common carotid artery intimal medial 
thickness (mm) 0.66 (0.2) 0.68 (0.2) 0.003
Table 1. Hyperuricemia and cardiovascular disease risk factors in SHFS. *Phenotypes are shown as means 
(SD); NS – Not significant. **Hyperuricemia was defined as serum urate concentrations > 6 mg/dl in women 
and > 7 mg/dl in men.
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GWAS was first conducted in each of the three centers of the SHFS (Arizona, Oklahoma and Dakotas (North 
and South)), followed by a meta-analysis of all three centers. As a secondary aim, we aimed to identify American 
Indian-specific SNPs in SLC2A9, the gene most strongly associated with SU in this study.
Results
The current study included 3000 SHFS participants (1282 men and 1718 women) from three study centers, 
Arizona, North and South Dakota (Dakotas) and Oklahoma. The mean SU concentrations were 5.14 ± 1.5 mg/dl 
(4.6 ± 1.3 mg/dl in women and 6.0 ± 1.4 mg/dl in men); 4.9 ± 1.5 mg/dl, 5.2 ± 1.5 mg/dl, 5.3 ± 1.5 mg/dl in 
Arizona, Dakotas and Oklahoma respectively. Genetic analysis was conducted using rank-inverse-normal trans-
formed SU concentrations, which were regressed on covariates such as age, sex, and their interactions, diabetes 
status, and medications27,28.
MetaboChip data analysis. Metabochip genotyping was conducted in a subset of 2000 SHFS 
(Arizona = 300, Dakotas = 850, Oklahoma = 850) participants who were free of diabetes at visit 1. The final data 
set included 162,718 autosomal SNPs. MetaboChip data analysis, conducted in each of the three SHFS centers, 
revealed significant associations of SU with SLC2A9 SNPs (P < 4 × 10−7); rs13145758, rs9998811, rs7862063 in 
Arizona and rs4481233 in Dakotas and Oklahoma. The minor allele frequencies (MAFs) ranged between 25 and 
44%, and the effect sizes (proportion of the residual phenotypic variance that is explained by the minor allele of 
the SNP) ranged between 4 and 6% (Table 2). The most significant SNP in Arizona was rs13145758 whereas it 
was rs4481233 in Oklahoma and the Dakotas. Several other SNPs showed associations at P < 1 × 10−5 including 
rs4148155, rs1481012 and rs2231142 of ABCG2.
Meta-analysis. As a follow-up, we conducted a meta-analysis of SNPs associated with SU concentrations in 
each of the three centers. The order of the MetaboChip-wide significantly associated SNPs remained similar after 
meta-analysis, but with increased statistical significance (most significant SNP - rs4481233 (A/G); P = 9 × 10−20) 
(Table 3). Individuals with G alleles of rs9998811, rs4148155 and rs1481012 and A alleles of rs7696092, rs4481233, 
rs13145758 and rs2231142 had lower SU concentrations as compared to other alleles. Table 3 shows these top 
seven SNPs that exhibited significant associations. Figure 1 shows the Manhattan plot with meta-analysis results 
showing strong association of SLC2A9 and ABCG2 variants on chromosome 4 with SU.
SNP
Minor 
Allele MAF P-value β SE
Effect 
Size Gene Gene loc Chr Chr pos hg18
Arizona
rs13145758 A 0.43 1.1 × 10−10 −0.35 0.05 0.06 SLC2A9 Intron 4 9981997
rs9998811 G 0.44 7.4 × 10−10 −0.33 0.05 0.06 SLC2A9 Intron 4 9966477
rs7862063 G 0.41 4. 5 × 10−8 0.29 0.05 0.04 — — 9 110002036
rs4481233 A 0.41 2.3 × 10−6 −0.26 0.05 0.03 SLC2A9 Intron 4 9956079
rs6688009 A 0.01 9. 1 × 10−6 1.07 0.24 0.03 PPAP2B Intron 1 24593576
Dakotas
rs4481233 A 0.25 6. 7 × 10−8 −0.29 0.05 0.04 SLC2A9 Intron 4 9956079
rs7696092 C 0.19 1. 6 × 10−6 −0.29 0.06 0.03 SLC2A9 Intron 4 10025320
rs179409 G 0.45 3.4 × 10−6 −0.23 0.05 0.03 KCNQ1 Intron 11 2483882
rs9998811 A 0.41 4.2 × 10−6 −0.22 0.05 0.03 SLC2A9 Intron 4 9966477
rs13145758 G 0.40 5.1 × 10−6 −0.22 0.05 0.03 SLC2A9 Intron 4 9981997
rs7947391 A 0.22 5.6 × 10−6 −0.26 0.06 0.02 NPAS4 Intron 11 66186882
Oklahoma
rs4481233 A 0.30 3.3 × 10−9 −0.30 0.05 0.06 SLC2A9 Intron 4 9956079
rs9998811 A 0.46 5.8 × 10−7 −0.23 0.05 0.04 SLC2A9 Intron 4 9966477
rs4148155 G 0.20 1.1 × 10−7 0.29 0.06 0.03 ABCG2 Intron 4 89054667
rs2231142 A 0.20 1.1 × 10−6 0.29 0.06 0.03 ABCG2 Missense 4 89052323
rs1481012 G 0.20 1.1 × 10−6 0.29 0.06 0.03 ABCG2 Intron 4 89039082
rs7696092 C 0.29 2.1 × 10−6 −0.25 0.05 0.04 SLC2A9 Intron 4 10025320
rs13145758 G 0.45 2.7 × 10−6 −0.22 0.05 0.03 SLC2A9 Intron 4 9981997
rs746075 A 0.36 2.8 × 10−6 0.22 0.05 0.04 NUCB1 Intron 19 49416936
Table 2. Genome-wide association analysis of serum urate stratified by center. *SNP: single nucleotide 
polymorphism; MAF: minor allele frequency; P-value: P-values from measured genotype analysis; β: beta 
coefficient of the SNP; SE: standard error; Effect Size: Proportion of the residual phenotypic variance that is 
explained by the minor allele of the SNP; Gene loc: Gene location; Chr pos: chromosome position in base pairs; 
SLC2A9: solute carrier family 2, member 9; PPAP2B: phosphatidic acid phosphatase type 2; KCNQ1: voltage 
gated KQT-like subfamily Q, member 1; ATP13A5: ATPase type 13A5; ABCG2: ATP-binding cassette family G, 
member 2; NUCB: Nucleobindin.
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SLC2A9 sequence variants. To identify American Indian-specific SNPs in our top hit, we conducted tar-
geted sequencing of key regions of SLC2A9 including all exons, 74Kb of introns and 10 kb of upstream and down-
stream regions of the gene in 902 SHFS founders (individuals with offspring in the SHFS but no parents). A total 
of 427 autosomal, polymorphic variants were identified in the 96 kb region of SLC2A9 that was sequenced. These 
included 233 single nucleotide polymorphisms (SNPs; MAF ≥ 1%); 125 single nucleotide variants (SNVs; minor 
allele count ≥2); 26 singletons (variants found only in one of our samples); and 43 indels/triallelics (insertions or 
deletions or more than two alleles); 117 variants of these were novel based on comparison with dbSNP database 
(Supplementary Table 1). The 233 SNPs were then genotyped in all 3000 SHFS (Arizona = 586, Dakotas = 1208, 
Oklahoma = 1206) participants of all three centers. A total of 89 SNPs were associated at the significance level 
of P < 2 × 10−4 after adjustment for multiple tests. Table 4 lists the top 10 SNPs and their associations with SU 
concentrations. The rest of the SNPs and their association with SU are shown in Supplementary Table 2. Figure 2 
shows LD patterns of these 10SNPs in the SHFS and other ethnicities from the 1000 Genomes project29.
Genetic analysis conditional on significant SLC2A9 and ABCG2 variants. To identify secondary 
signals for loci associated with SUA, we repeated GWAS of SU conditional on the significant SLC2A9 and ABCG2 
variants in each center30. We found suggestive evidence of association of SU concentration with SNPs in nucle-
obindin (NUCB1-AS1) (rs746075, P = 2.0 × 10−6) in Oklahoma and neuronal PAS-domain containing protein 4 
(NPAS4) (rs7947391, P = 3.2 × 10−6) in the Dakotas. No significance or suggestive level of significance was found 
for SNPs in the Arizona center.
Replication of SU associations in independent cohorts. To ascertain whether SU-associated SNPs, 
particularly the novel ones, identified in American Indians are generalizable to other ethnicities, we conducted 
replications in four different cohorts: Europeans (publicly available data)15, Mexicans-mestizos31, Indians32 and 
East Asians (publicly available data)33. Table 5 shows the SNPs identified in SHFS along with the association 
results in the other four ethnicities. SNPs rs62293300 and rs4385059 of SLC2A9 were associated with SU with 
direction of the effect in American Indians being consistent with Mexican-mestizos. rs4385059, rs28592748 and 
rs7696092 of SLC2A9 were associated with SU in all three populations. However, the direction of the effect was 
same in American Indians, Mexican-mestizos and Indians but different in Europeans and East Asians. The SU 
SNP Allele1 Allele2 Zscore P-value Direction Gene Gene loc Chr
Chr pos 
hg18
rs4481233 A G −9.28 1.7 × 10−20 — SLC2A9 Intron 4 9956079
rs9998811* A G −9.02 1.8 × 10−19 — SLC2A9 Intron 4 9966477
rs7696092 A C 7.78 7.2 × 10−19 +++ SLC2A9 Intron 4 10025320
rs13145758* A G 8.98 2.8 × 10−14 +++ SLC2A9 Intron 4 9981997
rs4148155* A G −5.98 2.2 × 10−09 — ABCG2 Intron 4 89054667
rs2231142* A C 5.94 2.8 × 10−09 +++ ABCG2 Missense 4 89052323
rs1481012* A G −5.94 2.9 × 10−09 — ABCG2 Intron 4 89039082
Table 3. Variants associated with serum urate in meta-analysis of the three centers. *SNPs are in linkage 
disequilibrium (LD; r2 > 0.90); SNP: single nucleotide polymorphism; P-value: P-values from meta-analysis; 
Gene loc: Gene location; Chr pos: chromosome position in base pairs; SLC2A9: solute carrier family 2, member 
9; ABCG2: ATP-binding cassette family G, member 2.
Figure 1. Genome-wide association analysis shows strong association of serum urate with SLC2A9 and ABCG2 
SNPs.
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associations with NPAS4 SNP rs7947391 was significantly replicated in the cohort of East Asians with the direc-
tion of the effect being same as American Indians and Europeans in contrast to Mexican- Mestizos and Indians. 
rs746075 of NUCB1 SNP was not associated with SU in any of the replication cohorts.
Discussion
Our extensive association analysis using genome-wide as well as candidate gene SNPs in American Indians of 
the SHFS showed that uric acid transporters SLC2A9 and ABCG2 are key genes regulating SU concentrations. 
Previously, significant heritability was obtained, and linkages were localized for SU concentrations in American 
Indian participants of the SHFS27. Also, our previous candidate gene study replicated 7 SLC2A9 gene polymor-
phisms in these participants in all centers combined and when stratified by recruitment center28. However, so far 
no genome-wide analyses for SU have been reported in American Indians. In this regard, our MetaboChip data 
represents for the first time a detailed genome-wide investigation to identify genetic factors affecting the variation 
in SU in this population.
The top SNPs from our SU association analysis belonged to gene SLC2A9 located on chromosome 4 confirm-
ing results from previous studies from our and other groups14–22. The SNPs rs4481233, rs9998811, rs7696092 and 
rs3145758 were consistently associated with SU across centers. Our meta-analysis reproduced and strengthened 
our genome-wide MetaboChip results that were found for all the three study centers separately. In addition to 
SLC2A9, ABCG2 variants also significantly affected SU concentrations, which further implicates uric acid trans-
porters in the regulation of SU concentrations.
Identification of genetic variants underlying complex traits in minority populations in the US is challeng-
ing as they are underrepresented in genetic association studies and databases23, particularly Native Americans. 
Previous studies from our group involving minority populations such as Mexican Americans19, Zuni Indians20 
and Hispanic children21 have shown SLC2A9 to be the key gene affecting SU concentrations. The same has been 
shown by others in Europeans14,15, Asians16,17 and African Americans12,22. However, the associated variants seem 
to differ by population. Three recent studies have found significant association of SU with rs2231142 of ABCG2 
and rs7678287 of SLC2A9 in Mexican-mestizos31 and rs2231142 of ABCG2 and rs3775948 of SLC2A9 in Indians32 
and rs7679724 of SLC2A9 and rs4148155 of ABCG2 in Japanese individuals33. While rs2231142 and rs4148155 
of ABCG2 and rs3775948 were strongly associated with SUA in our study, rs7678287 and rs7679724 were not 
associated with SU in either individual centers or in the meta-analysis.
Our MetaboChip (center-specific and meta-analysis) association analysis has consistently shown rs4481233 of 
SLC2A9 to be strongly associated with SU concentration, further confirmed by our sequence variant analysis. An 
intronic variant, rs4481233, has been shown to be strongly associated with urate and gout34–36. The minor allele 
(A) of rs4481233 has been shown to be associated with lower concentrations of SU34 replicated by our study where 
SU was decreased by 0.32 mg/dl with every allele of the minor allele. Similar results have also been reported in a 
GWAS of untargeted serum metabolomics in about 3000 individuals from two large population-based European 
cohorts where rs4481233 was found to be strongly associated with urate35,36. Although intronic, rs4481233 is in 
high LD with missense variant rs16890979 and is part of a LD block that contains the polymorphic Alu elements37 
and regulatory motifs for Ets- and TCF12-family of transcription factors38 with potential for affecting splicing 
and gene expression.
We also found significant associations of SU with SNPs rs2231142, rs4148155, and rs1481012 (all three in 
LD) belonging to ABCG2, yet another uric acid transporter gene. Notably, rs2231142 is a missense variant of 
ABCG2 and is likely functional. This variant has been extensively reported to be associated with SU in several 
populations including Mexican-mestizos31, Mexican Americans13,39, European Americans, African Americans, 
and Asian populations12–17, although SLC22A12 has been shown to be strongest gene to be associated with SU 
in East Asians18. ABCG2 variants had not only been shown to be associated with SU concentrations, but also 





Allele MAF P-value β SE
Effect 
Size
rs4481233 9956079 G/A 0.30 4.2 × 10−24 −0.35 0.03 0.05
rs11723439 9951819 G/A 0.28 1.5 × 10−23 −0.35 0.03 0.05
rs28592748 9998605 G/A 0.25 2.7 × 10−22 −0.35 0.04 0.05
rs7669607 9997801 G/A 0.25 8.2 × 10−22 −0.35 0.04 0.05
rs13111638 9996890 G/A 0.23 1.4 × 10−21 −0.36 0.04 0.05
rs10939650 9998440 A/G 0.35 4.1 × 10−21 −0.31 0.03 0.04
rs4529048 9997112 A/C 0.36 5.0 × 10−21 −0.31 0.03 0.04
rs3733588 9997303 A/G 0.35 7.3 × 10−21 −0.31 0.03 0.04
rs1014290 10001861 A/G 0.35 7.6 × 10−21 −0.31 0.03 0.04
rs4385059 9989233 A/G 0.23 3.6 × 10−20 −0.34 0.04 0.04
Table 4. SLC2A9 sequence variants associated with serum urate (Top 10 significant associations reported 
here). *SNPs after accounting for linkage disequilibrium (LD; r2 ≥ 0.80); SNP: single nucleotide polymorphism; 
Chr pos: chromosome position in base pairs; MAF: minor allele frequency; P-value: P-values from measured 
genotype analysis; β: beta coefficient of the SNP; SE: standard error; Effect Size: Proportion of the residual 
phenotypic variance that is explained by the minor allele of the SNP; Gene loc: Gene location.
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colorectal cancer43. This gene, however, was not associated with SU in a cohort of Zuni Indians, another American 
Indian group20.
Other SNPs that were linked to variation in SU concentrations were rs7862063, located on chromosome 9, 
and rs6688009 of phosphatidic acid phosphatase type 2 (PPAP2B or PLPP3) gene in the Arizona center. Studies 
have indicated a role for PPAP2B in adipogenesis44 and vascular inflammation45. It seems to have a protective 
role in endothelial dysfunction by negatively regulating inflammatory cytokines45. However, this association was 
not shown by our other two centers or replication cohorts. In the Dakotas, we observed marginal association of 
SU with rs179409 of potassium channel, voltage gated KQT-like subfamily Q, member 1 (KCNQ1) gene, which 
has been shown to associate with gout and hyperuricemia46,47. The potential mechanism seems to be through 
alterations in innate immunity47,48, though, these variants and our SNP are about ~3 Mb apart and also not in LD 
with each other. Therefore, these associations need further investigations. KCNQ1 has been widely reported to 
be associated with body mass index and other anthropometric measures, and also with type 2 diabetes mellitus 
in several populations49–51.
Furthermore, our conditional analysis identified two novel genes, NUCB1 and NPAS4, to be associated with 
SU. Conditional analysis is a tool that is used to identify secondary signals that may be otherwise masked by the 
strong effects of lead SNPs30. The NUCB1 and NPAS4 SNPs were associated with lower SU concentrations and 
found only in the Oklahoma and Dakota centers, respectively. Center-specific statistics for these two SNPs show 
considerable differences in minor allele frequencies between them, rs7947391 of NPAS4 – 0.05, 0.22, 0.13 and 
rs746075 of NUCB1 – 0.31, 0.49, 0.36 in AZ, DK, OK, respectively. NUCB1 is a Golgi-protein with potential 
role in calcium homeostasis and immunity52. It is believed to control protein unfolding in Alzheimer’s disease53 
and stimulate insulin secretion54. NPAS4 is a neuronal transcription factor involved in the regulation of cogni-
tive functions in the brains55. Its association with SU in our study was replicated in Japanese individuals of East 
Asian ancestry33. In addition, this study also found a significant expression quantitative trait locus (eQTL) for 
NPAS4 in monocytes (p = 6 × 10−10). The common link between NPAS4 and SU seems to be oxidative stress 
and inflammation-associated ischemia in the brain56. This assumes significance considering the increasing 
importance of uric acid in cognitive, and neuronal function and its recognition as an important biomarker for 
Parkinson’s disease57,58.
Sequence analysis of key regions of SLC2A9 identified 384 SNPs/SNVs/singleton variants, 117 variants of these 
were novel based on comparison with dbSNP database. Several of those SNPs, including rs3775946, rs6826764, 
rs6823877, rs56239136, rs4697693, rs2240721, rs1107710, and rs7698858 have not been previously reported as 
affecting SU concentrations. One SNP (chr_pos: 4_10027969) was found to be novel. Although, most studies 
reported the SNPs in the SLC2A9 locus to be significantly associated with SU in different populations, SLC2A9 
variants such as rs3733585, rs6855911, rs1014290 and rs12499857 associated with SU in our study have also 
been linked to Parkinson’s disease59,60, type 2 diabetes61, anxiety disorders62 and nonsyndromic cleft palate63. Our 
results also showed that the minor alleles of most of these SNPs were associated with lower SU concentrations.
Figure 2. Comparison of LD patterns between ethnicities for top 10SU-associated SLC2A9 sequence variants.
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There are some limitations of the study. First, the MetaboChip may not be the best option for identifying SNP 
associations with SU in this population. Secondly, the sample size for GWAS may be only moderate. However, 
family-based studies, a key strength of this study, are favorable for detection of significant associations and/or 
gene discoveries as they are homogenous, are robust to the effects of population stratification and have increased 
power to detect novel associations due to reduced residual variance64. Another strength of this study is inclusion 
of an understudied population with unique genetic and environmental background and availability of extensive 
covariate information.
In summary, our results replicated known associations of uric acid transporters with SU in a minority pop-
ulation of American Indians and demonstrated potential novel associations of SU with neuronal-related genes 
which need further investigation.
Methods
Study population: strong heart family study (SHFS). The Strong Heart Family Study (SHFS) is a 
genetic study of CVD risk in American Indians. Description of the phenotypes, SU measurement techniques, and 
other related analytical approaches have been detailed elsewhere27,28. In short, the SHFS is a multi-center fami-
ly-based genetic study in American Indian communities from Arizona, the Dakotas, and Oklahoma, which are 
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Table 5. Replication of the associations observed in SHFS. aPLPP3 or PPAP2B: Phospholipid phosphatase 3; 
SLC2A9: Solute carrier family 2 member 9; KCNQ1: Potassium voltage-gated channel subfamily Q member 
1; NPAS4: Neuronal PAS domain protein 4; NUCB1: Nucleobindin 1; bSNP: Single nucleotide polymorphism 
(index SNP); cProxy SNP: SNP in high LD with the index SNP. Used by replication studies when the original 
SNP data were not available; dhttp://metabolomics.helmholtz-muenchen.de/gugc/ and http://useast.ensembl.
org/Homo_sapiens/Variation/Explore?r=4:9950721; eKanai et al. 2018; Nature Genet. fβ (SE): Beta coefficient 
(standard error).
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diabetic nephropathy. Approximately 3000 members (including 902 founders) belonging to multigenerational 
families of Arizona, North and South Dakota (Dakotas), and Oklahoma participated in the study. These individ-
uals aged 14 to 93 years were recruited without regard to disease status in 199865,66. The Indian Health Service 
Institutional Review Board and the Institutional Review Boards from Texas Biomedical Research Institute and the 
University of North Carolina at Chapel Hill approved the SHFS protocol and all subjects gave informed consent. 
For participants under the age of 18 years, informed consent was obtained from their parent or legal guardian. 
Study design and methods of the SHFS are in accordance with institutional guidelines and have been described 
previously65,66.
Phenotyping. Blood was collected after an overnight fast. Uric acid concentrations in serum were assayed in 
the SHFS central laboratory by the uricase and peroxidase method67.
Genotyping. MetaboChip data. Blood collected from individuals who were free of diabetes at baseline visit 
(n = 2000) was used for this study. Cardio-Metabo DNA Analysis BeadChip (Illumina catalog# WG-310-1001 or 
WG-310-1002) was used for genotyping. The MetaboChip contained 196,725 markers. The original annotation 
file for the Cardio-Metabo BeadChip is Metabochip_Gene_Annotation. Simwalk2 was used to remove genotyp-
ing inconsistencies68. Participants were excluded if genotyping call rate was <95% (n = 3). SNPs were excluded 
if the call rate <98% (n = 0), not autosomal (n = 250), no data after imputation (n = 33,599) or Hardy-Weinberg 
equilibrium P < 1 × 10−5 (n = 20,067). Pairwise correlations (r2) between markers were calculated to estimate 
linkage disequilibrium (LD). The final cleaned, imputed data set includes 162,718 autosomal marker information 
available for 2000 American Indian participants.
Sequencing of SLC2A9 gene. We sequenced 96 kb of the SLC2A9 gene, using a Illumina’s TruSeq Custom 
Amplicon kit and MiSeq Sequencer, in 902 founders of multigenerational families. The target regions contained 
all exons, 2.2 kb, 74 kb of introns, and 10 kb of upstream and downstream region of the gene. Illumina gener-
ated sequence data (BAM files) were aligned to the Human Genome Reference Sequence version 37.1 (hg19). 
Variants were called, recalibrated and QC’d using the Genome Analysis Toolkits (GATK v.3.3) Haplotype Caller69. 
Pairwise correlations (r2) between markers were calculated to estimate linkage disequilibrium (LD). We identified 
427 autosomal, non-monomorphic variants, 384 of which affected a single base (233 single nucleotide polymor-
phisms (SNPs; MAF ≥ 1%); 125 single nucleotide variants (SNVs; minor allele count ≥ 2); 26 singletons (vari-
ants found only in one of our samples)); and 43 were indels/triallelic (insertions or deletions or more than two 
alleles). Out of the forty-three indel/triallelic vaiants, 14 variants were listed in dbSNP (rs140391260, rs5856025, 
rs34839464, rs137899691, rs35950306, rs139025036, rs35614040, rs58702202, rs112058434, rs66622652, 
rs60841869, rs142713311, rs3834235, and rs66943961). The MAFs of all variants ranged between 0.1 and 49%, 
except for indels/triallelic.
Statistical analysis. Genotype cleaning and population stratification assessment. Genotype frequencies for 
each SNP were estimated and tested for departures from Hardy-Weinberg equilibrium in the software package, 
Sequential Oligogenic Linkage Analysis Routines (SOLAR)70. Also, we used principal component (PC) scores to 
model differences in ancestral contributions among study participants for MetaboChip data. PCs were calculated 
using the unrelated SHFS founders and a subset of 15,158 selected SNPs (r2 < 0.1; MAF > 0.05). PCA was per-
formed on a matrix of “doses” (copies of minor allele) for the selected SNPs, using “prcomp” in R. The PC scores 
were then predicted for all genotyped individuals using the PCA model fit to the founder data71,72. While no PC 
accounted for a large percentage of total variance in genotypes scores, the first four PCs account for substantially 
more than the rest and were, therefore, included as additional covariates in association analyses.
Measured genotype analysis (MGA). The association of SNPs with SU was estimated using a measured 
genotype analysis (MGA)73 executed in SOLAR after accounting for family relationships based on variance com-
ponents approach. This approach allows us to account for the non-independence among family members. To 
minimize the problem of non-normality, the SU data were inverse-normal-transformed using SOLAR. All anal-
yses involved adjustment for the covariate effects (see results). The appropriate significance level was determined 
to be P < 4 × 10−7 for MetaboChip data, and P < 2 × 10−4 for sequence data after correcting for multiple tests.
METAL. METAL74 software was used to perform meta-analysis of GWAS results taken from the three study 
centers, each study containing individual genome-wide MetaboChip association results for multiple markers.
Conditional analysis and functional annotation of significant variants. To identify additional 
independent loci that are associated with SU concentrations, we performed association analysis conditioned on 
significant SLC2A9 and ABCG2 SNPs30.
Replication studies. Mexican-mestizos studies. Seven of the SNPs that reached genome-wide suggestive 
significance in the discovery phase were tested for replication in an independent cohort of Mexican Mestizo indi-
viduals (1,061 children and 1,101 adults). Population characteristics, biochemical measurements and genotyping 
have been previously described. Briefly, genotypes of six SNPs were obtained from a Multi-Ethnic Genotyping 
Array (MEGA, Illumina, San Diego, CA, USA), while rs7947391 genotypes were imputed using 1000 Genomes 
Project and Native Mexican individuals as ref. 31. Associations with SUA were tested separately in children 
and adults in a linear mixed model that considered the genetic relatedness matrix as a random effect, while 
genotype, age, sex and BMI percentile or body mass index (kg/m2) were included as fixed effects. Results were 
meta-analyzed with the inverse variance method75.
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Indian diabetes consortium. The study participants included the members of the INdian DIabetes 
Consortium (INDICO)76. Details of the study recruitment and phenotype measurements are given in Giri et al.32. 
In short, samples were enrolled in the study by conducting diabetes awareness camp organized in various parts of 
North India. Prior informed written consent was obtained from the study participants. The study was approved 
by the Human Ethics Committee of the CSIR-Institute of Genomics and Integrative Biology and the All India 
Institute of Medical Sciences research Ethics Committee. The study was conducted in accordance with the princi-
ples of the Helsinki Declaration. Genotyping was conducted using the Illumina Human 610-quad bead chip array. 
Association with SU concentrations was tested using linear regression models in PLINK77. Sex, age, BMI and first 
three principal components of genotypes were used as covariates in the model.
European studies. Replication analysis in Europeans was conducted with publicly available data 
from Kottgen et al.15. We used the summary statistics from meta-analysis of serum urate from the arti-
cle by Kottgen et al. The meta-analyses comprised of 14 studies totaling 2,115 cases and 67,259 controls 
[http://metabolomics.helmholtz-muenchen.de/gugc/, http://useast.ensembl.org/Homo_sapiens/Variation/
Explore?r=4:9950721-9951721;source=dbSNP;v=rs1079128;vdb=variation;vf=250145324].
East asian studies. Replication analysis in East Asians was conducted with publicly available data from 
Kanai et al.33. We used the summary statistics from a genome-wide association analysis of serum uric acid in 
Japanese individuals from Kanai et al. The GWAS was conducted for 58 quantitative traits, including serum 
uric acid, in 162,255 individuals [https://www.ncbi.nlm.nih.gov/pubmed/?term=Kanai+M%2C+2018%2C 
Nature + Genetics]78 This research was supported by the Tailor-Made Medical Treatment Program (the BioBank 
Japan Project) of the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) and the Japan 
Agency for Medical Research and Development (AMED)78.
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